RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Alexion Pharmaceuticals EBIT 2024

Alexion Pharmaceuticals EBIT

0 USD

Alexion Pharmaceuticals Dividend yield

Ticker

ALXN

ISIN

US0153511094

WKN

899527

In 2024, Alexion Pharmaceuticals's EBIT was 0 USD, a 0% increase from the 0 USD EBIT recorded in the previous year.

The Alexion Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2025e-
2024e-
2023e-
2022e-
2021e-
20202.8
20192.13
20181.48
20170.76
20160.76
20150.62
20140.92
20130.58
20120.4
20110.24
20100.15
20090.09
20080.03
2007-0.1
2006-0.14
2005-0.06
2004-0.07
2003-0.08
2002-0.06
2001-0.04

Alexion Pharmaceuticals Aktienanalyse

What does Alexion Pharmaceuticals do?

Alexion Pharmaceuticals Inc. is a US biotechnology company specializing in the development and commercialization of drugs for the treatment of rare diseases. It was founded in 1992 and is headquartered in Boston, Massachusetts. The history of Alexion began with the discovery of the protein C5a, which is responsible for the occurrence of inflammation. Alexion then developed the first medication, Soliris, specifically for the treatment of the rare genetic disease paroxysmal nocturnal hemoglobinuria (PNH). Soliris is classified as a monoclonal antibody and inhibits the protein C5a, which is responsible for inflammation. Alexion's business model focuses primarily on developing drugs for rare diseases. These diseases are unprofitable for most major pharmaceutical companies because they have a small patient base. However, Alexion has begun to identify and develop drugs for such diseases that are tailored to these specific patients. Such drugs are not suitable for the majority of the patient population as they are very expensive. Alexion is divided into several divisions focused on the development and launch of drugs for specific diseases. The most well-known division is PNH, but the company has also developed drugs for rare hematological, nephrological, neurological, immunological, and metabolic diseases. Alexion has also developed the ability to bring drugs to market faster than other pharmaceutical companies by employing innovative clinical trial methods. In addition to Soliris, Alexion has developed other drugs such as Ultomiris, Strensiq, and Kanuma. Ultomiris is a successor to Soliris and is used to treat PNH and aHUS. Strensiq is used for patients with hypophosphatasia, while Kanuma was developed for patients with lysosomal storage diseases such as children with Gaucher disease or Fabry disease. Alexion also collaborates with other companies to develop and market drugs for rare diseases. The most well-known example is the collaboration with the Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation to develop the drug ALXN1210, which Alexion hopes will surpass both Soliris and Ultomiris. The collaboration has the potential to provide groundbreaking treatment for PNH, aHUS, and other rare diseases. Overall, in recent years, Alexion Pharmaceuticals Inc. has become an important player in the market for rare diseases. The company has taken on challenging tasks by striving to uncover rare diseases and gaps and then finding new, unique solutions to treat these diseases. In the future, Alexion will continue its efforts in researching and developing drugs for rare diseases and will continue to provide innovative solutions and therapeutic approaches to improve the lives of patients. Alexion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Alexion Pharmaceuticals revenue by segment

In the annual report of the Alexion Pharmaceuticals share (US0153511094, 899527, ALXN), it breaks down its revenues into 1 segments: 1. Therapies. The Alexion Pharmaceuticals stock (WKN: 899527, ISIN: US0153511094, Ticker Symbol: ALXN) is a leading investment for investors interested in participating in the Health Care sector.

EBIT Details

Analyzing Alexion Pharmaceuticals's EBIT

Alexion Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Alexion Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Alexion Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Alexion Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Alexion Pharmaceuticals Stock

How much did Alexion Pharmaceuticals achieve in EBIT for the current year?

In the current year, Alexion Pharmaceuticals has achieved an EBIT of 0 USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Alexion Pharmaceuticals.

How has the EBIT of Alexion Pharmaceuticals developed in recent years?

The EBIT of Alexion Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Alexion Pharmaceuticals?

The EBIT of Alexion Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Alexion Pharmaceuticals pay?

Over the past 12 months, Alexion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alexion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Alexion Pharmaceuticals?

The current dividend yield of Alexion Pharmaceuticals is .

When does Alexion Pharmaceuticals pay dividends?

Alexion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alexion Pharmaceuticals?

Alexion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Alexion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alexion Pharmaceuticals located?

Alexion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alexion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alexion Pharmaceuticals from 4/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/28/2024.

When did Alexion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/28/2024.

What was the dividend of Alexion Pharmaceuticals in the year 2023?

In the year 2023, Alexion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Alexion Pharmaceuticals pay out the dividend?

The dividends of Alexion Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Alexion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Alexion Pharmaceuticals

Our stock analysis for Alexion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alexion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.